San Diego-based Viking Therapeutics marked alone as a significant competitor from the weight loss drug current market in February after revealing promising details from a mid-stage trial of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when given for a weekly injection As well as in March the company un